Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · IEX Real-Time Price · USD
42.55
-0.23 (-0.54%)
At close: Jul 19, 2024, 4:00 PM
42.50
-0.05 (-0.12%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for RARE stock have an average target of 86.6, with a low estimate of 45 and a high estimate of 130. The average target predicts an increase of 103.53% from the current stock price of 42.55.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RARE stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 6 | 6 | 6 |
| Buy | 7 | 8 | 9 | 9 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 14 | 16 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Hold Reiterates $45 | Hold | Reiterates | $45 | +5.76% | Jul 18, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $115 | Buy | Reiterates | $115 | +170.27% | Jun 12, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $56 → $67 | Hold → Strong Buy | Upgrades | $56 → $67 | +57.46% | Jun 6, 2024 |
| Wedbush | Wedbush | Hold Maintains $47 → $48 | Hold | Maintains | $47 → $48 | +12.81% | May 31, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $83 → $76 | Strong Buy | Maintains | $83 → $76 | +78.61% | May 31, 2024 |
Financial Forecast
Revenue This Year
523.81M
from 434.25M
Increased by 20.62%
Revenue Next Year
633.50M
from 523.81M
Increased by 20.94%
EPS This Year
-6.77
from -8.25
EPS Next Year
-5.42
from -6.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 562.8M | 785.4M | 1.2B | 2.7B | 4.2B |
| Avg | 523.8M | 633.5M | 857.1M | 1.4B | 2.2B |
| Low | 491.5M | 533.3M | 671.5M | 825.3M | 1.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.6% | 49.9% | 82.5% | 214.1% | 201.2% |
| Avg | 20.6% | 20.9% | 35.3% | 63.7% | 54.4% |
| Low | 13.2% | 1.8% | 6.0% | -3.7% | -21.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.95 | -2.35 | -0.75 | 0.16 | 5.00 |
| Avg | -6.77 | -5.42 | -3.47 | -1.54 | 3.04 |
| Low | -7.36 | -6.61 | -5.92 | -3.98 | 0.62 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.